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ABSTRACT 
ENHANCEMENT OF ABAMECTIN METABOLISM BY DEXAMETHASONE (DEX), 
3-METHYLCHOLANTHRENE (3-MC), OR PHENOBARBITAL (PB) INDUCTION 
IN COLORADO POTATO BEETLE (CPB), LEPTINOTARSA DECEMLINEATA SAY: A 
MODEL FOR OXIDATIVE METABOLIC RESISTANCE 
MAY 2001 
KYONG S. YOON 
B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor J. Marshall Clark 
Difference in abamectin metabolism betweeen DEX-, 3-MC-, or PB-induced and 
non-induced susceptible (SS) and resistant (AB-F) strains of CPB was investigated. 
DEX- and 3-MC-induced SS CPB exhibited a significantly decreased mortality response 
to abamectin compared to non-induced SS beetles. In DEX- and 3-MC-induced SS 
beetles, the abamectin mortality of the piperonyl butoxide (PBO) synergized SS beetles 
was significantly higher compared to unsynergized but induced SS beetles. DEX-induced 
SS beetles produced a significantly higher amount of the 3”-0-desmethyl [3H]avermectin 
Bia (3”DM) metabolites (63.9% more) compared to non-induced SS beetles. 3-MC- 
induced SS beetles produced significantly higher amounts of 24-hydroximethyl (24-OH), 
26-hydroxymethyl (26-OH), and 3’DM [ HJavermectin Bia metabolites (50.9, 53.5, and 
53.2% more, respectively) compared to non-induced SS beetles. DEX-induced 
v 
microsomes prepared from SS beetles produced significantly higher amount of 3”DM 
metabolite (2.3-fold more) than non-induced microsomes. PBO or troleandomycin (TAO) 
i 
synergized microsomes produced significantly less 3”DM metabolite (9.3-fold and 10.1- 
fold less, respectively) compared to unsynergized but induced microsomes. These 
findings substantiate a cytochrome P450 monooxygenase (P450)-based resistance 
mechanism initially reported by Argentine et al. (1992). We are currently evaluating a 
P450 gene family that is inducible with DEX. 
vi 
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CHAPTER I 
INTRODUCTION 
A. Colorado Potato Beetle 
The Colorado potato beetle (CPB. Leptinotarsa decemlineata, Say) has been a 
serious insect pest of potatoes since the 1860s in North America and since the 1920s in 
Europe (Radcliffe, 1982). Control efforts rely primarily on insecticides due to their cost 
effectiveness, with insecticides being applied to 94 % of the total potato acreage in 1995 
(USDA Census, 1997). The use of insecticides without knowledge of resistance 
mechanisms and without proper management strategy resulted in wide spread control 
failures and rapid development of resistance to all major classes of insecticides. There 
still remains relatively little information concerning biochemical mechanisms of 
resistance in CPB. Rose and Brindley (1985) reported that a carbaryl-resistant strain of 
CPB had elevated level of NADPH-dependent cytochrome c reductase and elicited 
enhanced excretion of carbaryl and carbary 1 metabolites. However, they did not show 
that the elevated level of NADPH-dependent cytochrome c reductase was the actual 
cause of carbaryl resistance. Soderlund et al., (1987) reported a number of metabolic 
pathways for fenvalerate in CPB, including alkyl-hydroxylation, ester cleavage and 
diphenyl ether cleavage. Argentine et al. (1989) reported synergism with an esterase 
inhibitor, S, S, S-trybutyl phosphorotrithioate (DEF), and moderate levels of synergism 
with the glutathione-S-transferase inhibitor, diethyl maleate, and the monooxygenase 
1 
inhibitor, piperonyl butoxide (PBO), in a multiple insecticide-resistant strain of CPB. In 
subsequent studies with pharmacokinetic approaches and various enzyme activity assays, 
including a crude acetylcholinesterase (AChE) assay, they determined that 
azinphosmethyl resistance in CPB (136-fold more resistant than susceptible strain) was 
due to multiple factors including reduced penetration, enhanced xenobiotic metabolism, 
and site insensitivity caused by altered AChE (Argentine et al., 1994). Zhu and Clark 
(1995) subsequently showed lower substrate affinities and hydrolyzing efficiency of the 
AChE purified from the resistant strain. 
Argentine et al., (1989) reported that permethrin resistance in CPB (55 times 
more resistant than susceptible strain) was principally due to a sex-linked, semirecessive 
factor conferring cross-resistance to other pyrethroids and DDT. Argentine et al. (1995) 
subsequently determined two contributing factors, an increased level of carboxylesterase 
activity (permethrin carboxylesterase) and a neuronal site insensitivity (knockdown 
resistance, kdr) are associated with permethrin resistance. Lee et al. (1999) reported 
single amino acid substitution in premethrin resistant strain of CPB corresponding to the 
L1014F mutation in the housefly Vsscl sodium channel was caused the kdr-like 
resistance trait. 
Argentine et al. (1992) reported that abamectin resistance in the CPB was 
determined to be autosomal, incompletely recessive, and polygenic. They showed that 
two resistant strains elicited abamectin tolerance (15- to 23-fold), high levels of 
synergism to PBO, moderate levels of synergism to DEF, and produced elevated levels of 
2 
[3H]avemectin Bia metabolites under in vivo and in vitro conditions compared to 
susceptible strain indicating a metabolic mechanism of resistance, which appears to be 
primarily oxidative. 
B,Oxidative Metabolism and Cytochrome P45Q Monooxygenases (P450s) 
The P450s (mixed function oxidases, polysubstrate monooxygenases) are a 
superfamily of heme-thiolate proteins (Palmer and Reedijk, 1991), which involve 
synthesis and degradation of endogenous compounds and that catalyze xenobiotic 
metabolism by oxidation, reduction, peroxidation, and monooxygenation reactions 
(Nelson et al., 1993). For example, insect P450s are involved in synthesis of 
ecdysteroids and juvenile hormones and metabolism of insecticides (Hammock, 1975; 
Grieneisen et al., 1993; Taylor and Feyereisen, 1996). Most eukaryotic P450s are 
composed of approximately 500 amino acids (—50- to 60-kDa) and are found in 
mitochondria and endoplasmic reticulum of various tissues and organs, such as plant 
tissues, mammalian liver, and fat body of insects (Feyereisen, 1999; Chappie, 1998). A 
highly conserved region is found in the heme binding site, which contains the signature 
sequence FXXGXXXCXG (Feyereisen, 1999). The heme binding site consists of iron 
protoporphyrin XI bound to the protein by hydrophobic force, a thiolate anion from a 
cysteine residue, which mainly contributes to the enzyme catalytic activity, and water 
molecule that is exchangeable with 02 or CO, competitively, when the iron atom is 
reduced to the ferrous form (Porter and Coon, 1991). 
3 
Oxidations by P450s are one of the important reactions of xenobiotic metabolism. 
The general stoichiometry of oxidations (R + NAD(P)H + H+ + O2 -> RO + NAD(P)+ + 
H2O, R represents the substrate) by P450s are tightly coupled reactions (Guengerich, 
1996; Feyereisen, 1999). After substrate binding to the oxidized form (Fe3+), the P450- 
A_ 
substrate complex is reduced by obtaining an electron from NADPH + H+. Molecular 
oxygen binds to the Fe2+-P450-substrate complex to start oxidative reaction. The 
intermediate product (R-Fe3+(C>2')) accepts a second electron from NADH and results in 
the R-Fe (O2 ) reactive intermediate. Molecular oxygen is split to 20‘, which allows 
formation of R-(Fe-0)3+ and H2O. At this stage, several resonance forms allow up to 60 
different reactions to occure, including hydroxylation, epoxidation, 0-, N-, and S- 
dealkylation, and N- and S-oxidation. In the hydroxylation reaction, for example, 
hydrogen abstraction from the substrate produces transient hydroxyl and carbon radicals, 
which results in oxygen insertion into the substrate (Porter and Coon, 1991). O- 
dealkylations occur for ethers and esters by hydrogen abstraction resulting in production 
of oxygen and carbon radicals, which led to the hydroxyl group attachment. 
Rearrangement reactions produce dealkylated compounds (Guengerich, 1996). 
Induction of P450s is a well known but its exact mechanism is not well 
understood (Feyereisen, 1999). Multiple induction mechanisms are possible because 
complex regulation is likely involved in P450 expression. Enhanced transcription and 
post-transcriptional stabilization are two extensively studied regulation mechanisms of 
P450s that are induced by several xenobiotic compounds (Porter and Coon, 1991). The 
4 
induction mechanism of CYP1A1, a member of P450s inducible by foreign chemicals 
such as 3-methylcholanthrene (3-MC, Figure 1.1) and tetrachlorodibenzo-/?-dioxin 
(TCDD), is relatively well characterized. The first step of CYP1A1 induction is binding 
of the inducing chemical to the aryl hydrocarbon (Ah) or TCDD receptor, which is 
associated with heat shock protein 90 (hsp90) as an inactivated protein complex in the 
hepatic cytosol (Poland et al., 1976; Matsushita et al., 1993). After binding, the 
receptor protein dissociates from hsp90 and binds to the Ah nuclear translocator protein 
(Arnt). The Ah-Arnt complex is transferred into the nucleus and binds to the xenobiotic 
responsive element (XRE) in the 5’-flanking region of CYP1A1 resulting in enhancement 
of transcription (Swanson and Bradfield, 1993). Other subfamilies, such as human and 
mouse CYP1A2, do not have a consensus XRE but are still inducible with TCDD, 
suggesting indirect transcriptional or post-transcriptional induction process is involved 
(Porter and Coon, 1991). 
The mechanisms of induction for other P450s are less well understood. CYP2B 
subfamilies, including CYP2B2 and CYP2B10, are inducible with barbiturate compounds 
such as phenobarbital (PB, Figure 1.1). Receptor or other factor (e.g. translocation 
protein) involvement in this induction mechanism is not clear but PB responsive elements 
in 5’-flanking region of CYP2B subfamily genes are characterized as inducer-mediated, 
cA-acting elements (Kim and Kemper, 1997; Honkakoski and Negishi, 1997; Stoltz et al., 
1998). 
5 
CYP3A subfamily is inducible with glucocoricoids such as 16a-carbonitrile 
(PCN) and dexamethasone (DEX, Figure 1.1). Glucocorticoid responsive elements 
(GRE) in 5’-flanking region of CYP3A are characterized as inducer-mediated, ds-acting 
elements (Huss et al., 1995; Quattrochi et al., 1995; Mahnke et al., 1997; Huss and 
Kasper, 1998; Pereira et al., 1998). Glucocorticoid receptor (GR) involvement in the 
CYP3A induction process is currently under debate but most researchers believe that GR 
is likely involved in CYP3A induction either directly or indirectly (Pereira et al., 1998). 
Even though the mechanism of induction is not completely understood, 
differential induction of P450 seems to be correlated with the chemical or physical 
characteristics of inducer. For example, water solubility of the inducer may play an 
important role; PB is highly water soluble (1 mg/ml), DEX has intermediate water 
solubility (0.1 mg/ml) and 3-MC is not water soluble. These three distinct compounds 
are prototypical inducers for CYP2B, CYP3A, and CYP1A subfamily, respectively. 
Therefore, we can postulate that the water solubility of substrate chemical may determine 
the induction of specific P450s that have an ability to metabolize the chemical or its 
analogs. Although analog-inducer metabolism is well established, more information 
about the structural activity relationship between inducer and its receptor is needed to 
elucidate this relationship. 
Piperonyl butoxide (PBO, Figure 1.2), one of methylenedioxyphenyl (MDP) or 
benzodioxole (BD) compounds, is known as a potent inhibitor of P450-mediated 
oxidative metabolism. Studies on inhibition mechanism of PBO indicate a tight binding 
6 
of PBO to P450, which inhibits CO binding (Matthews and Casida, 1970; Philpot and 
Hodgson, 1972). A theoretical interaction between the heme iron of the P450 and a 
carbene metabolite from the MDP compounds produced during the oxidation reaction is 
proposed to the inhibition mechanism (Dahl and Hodgson, 1979). 
Troleandomycin (TAO, Figure 1.2), a widely used antibiotic, is a specific 
inhibitor for CYP3 family of P450s (Maurel, 1996). The inhibition mechanism is 
similar with the inhibition mechanism of PBO. The first step is formation of a P450- 
TAO metabolite complex. The TAO metabolite is produced by the P450-dependent 
oxidation reaction and the complex is very stable and prevents CO binding and O2 
fixation, resulting in the blockade of the P450 activity (Pessayre et al., 1981). 
C. Abamectin 
Abamectin (MK-936) is a mixture of avermectins containing > 80% avermectin 
Bfa and < 20% avermectin B^. The avermectins are 16-membered macrocyclic lactones, 
consisting of the macrocycle backbone (C-l to C-2 and C-7 to C-19), a spiroketal unit (C- 
17 to C-28), a hexahydrobenzofuran unit (C-2 to C-8), and a disaccharide substituent at 
C-l3 (Fisher and Mrozik, 1984). During fermentation, four structurally-related 
avermectins (avermectin Ai, A2, Bi, and B2) are produced by the soil microorganism, 
Streptomyces avermitilis. These structurally-related compounds are further classified as 
major components: Aia, A2a, Bia and B2a by presence of secondary sidechain at C-25 and 
as minor components: An,, A2b, Bib and B2b by an isopropyl substituent at C-25 (Figure 
7 
1.3). In general, the avermectin Bia, Bib, or B2b are biologically more active than 
avermectin Aia, Aib, A2a or A2b- Furthermore, the avermectins with Bi component are 
commercially more important because those with B2 are inactive in some insect pest 
species such as Haemonchus contortus, the barber pole worm. 
The avermectins do not have antibacterial or antifungal activities and do not 
inhibit protein or chitin synthesis even though they have macrolides, which are 
structurally-related to antibacterial activity, and macrocyclic polyenes, which are 
structurally-related to antifungal activity (Fisher and Mrozik, 1989). Unique insecticidal 
and anthelmintic properties of the avermectins, however, were reported by many 
researchers (Burg et al., 1979; Egerton et al., 1979; Ostlind et al., 1979; and James et al., 
1980). Putter et al. (1981) reported its broad spectrum insecticidal activity. In their 
studies, avermectin Bla was determined as a highly toxic to several insect pests in the 
orders Coleoptera, Homoptera, Diptera, Orthoptera, Isoptera, Hymenoptera and 
Lepidoptera. 
Campbell et al. (1983) reported high antiparasitic activity of ivermectin, a 
synthetic avermectin with the double bond between C-22 and C-23 generated by 
reduction. They noted that the ivermectin was highly toxic to two major phyla of 
animal parasites; the Nemathelminthes, which includes the families Trichostrongyloidea, 
Rhabditoidea, Ascandoidea, Oxyuroidea, Spiruroidea, Filaroidea, and Trichuroidea and 
the Arthropoda, which includes families Sarcoptidae, Haematopinidae, and 
Linognathidae. They also suggested use of the ivermectin against Onchocerca volvulus, 
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a skin dwelling microfilariae causing human onchocerciasis (river blindness). The 
ivermectin clinical trial data (Phase I - III) for onchocerciasis in Africa was gathered 
during the period of 1982-1987. The data clearly showed that an annual single dose of 
ivermectin (150 pg/kg) was effective although the ivermectin was not a permanent cure 
for onchocerciasis (Greene et al., 1989). 
Several mechanisms of action for avermectin Bja have been investigated. 
Initially, Fritz et al. (1979) reported that avermectin Bia increased membrane 
permeability to chloride ions due to either agonistic interaction with GABA binding site 
or regulation of presynaptic GABA release. Kass et al. (1980) suggested avermectin Bia 
action as a GABA agonist or a GABA stimulator. Duce and Scott (1983, 1985) used the 
extensor tibiae muscle of locust, which was sensitive to GABA and led to inhibitory 
innervation, to investigate action site of avermectin Bia. They observed a reversible, 
dose-dependent, increase in chloride ion permeability at very low dose of avermectin (~ 
10'10 M) but irreversible increase in Cf permeability at higher dose of avermectin Bja (~ 
o 
10' M). The irreversible increase of Cl' continued even after removal of the avermectin. 
Pong and Wang (1982) identified a high affinity binding site of avermectin BJa in 
the mammalian cerebellum and reported that avermectin B]a stimulated GABA binding. 
Drexler and Sieghart (1984) also found a high affinity binding site of avermectin B]a but 
the avermectin Bia binding was partially inhibited in the presence of GABA. Olsen and 
Snowman (1985) noted that avemectin Bja (10" M) decreased GABA binding but 
increased GABA antagonist ([ HJbicuculline) binding. To resolve these contradictory 
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results, Huang and Casida (1997) investigated avermectin Bia binding on GABA-gated 
Cl' channel and found high and low affinity sites in cultured cerebellar granule neurones. 
They determined that these two different sites on the GABA-gated Cf channel had a dual 
effect with respect to the binding of avermectin Bia. Avermectin Bla activated the 
channel by binding to the high affinity site and blocked it when subsequent binding to the 
low affinity site occurred. 
An additional site of action for avermectin Bia, the glutamate-gated Cf channels, 
which are members of the inhibitory ligand-gated anion channel found in invertebrates, 
has been investigated to elucidate its structure and functional properties. Cully et al. 
(1994) expressed two cloned cDNAs (GluCla and GluCip that encoded the a and p 
subunits of glutamate-gated Cf channel, respectively) from the soil nematode, 
Caenorhabditis elegans, in Xenopus oocytes and found these heteromeric channels were 
sensitive to glutamate, a glutamate analog ibotenate and avemectin analogs. They also 
expressed homomeric channels formed from a-subunits and determined that the 
homomeric channels are sensitive to ivermectin but not to glutamate.' Conversely, the 
homomeric channels formed from p-subunits are sensitive to glutamate but not to 
ivermectin. The results suggest that glutamate gates the channels by binding to the p- 
subunit and ivermectin acts as a allostereic modulator by binding to a-subunit. Etter et al. 
(1996) reported that amino acid substitutions in the homomeric GluCla channel pore 
region altered the channel sensitivity to glutamate. Cully et al. (1996) functionally 
expressed the DrosGlua gene from Drosopila melanogester in Xenopus oocytes and 
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demonstrated similar results as reported by Etter et al. (1996). Although the Cully 
group did not establish the specific binding site of avermectins on the DrosGluCla 
channel, they clearly demonstrated that the channel was a target for avermectins. 
Blackhall et al. (1998) suggested that a mutated GluCla channel was associated with 
ivermectin resistance, which indirectly indicated interaction of avermectins with GluCla 
channels. 
Studies on metabolism of avermectins in vivo and in vitro using vertebrate and 
invertebrate organisms have elucidated the pharmacokinetics of avermectins and its 
metabolites. Chiu and Lu (1989) detailed the absorption, distribution and excretion of 
22,23-[ Hjivermectin in several vertebrate species including cattle, sheep, swine and rat. 
The absorption of ivermectin was carried out via gavage, subcutaneous, intramuscular, 
intravenous or intraperitoneal. Tissue fluid samples from slaughtered animals were used 
for the quantification of residual tissue concentrations of ivermectin. Urine and feces 
were collected over the experimental period to determine amount of excreted ivermectin. 
The concentration of residual ivermectin was comparatively high in liver and fat tissues 
and most excretion occurred in feces. Two major metabolites, 24-hydroxymethyl and 
3”-0-desmethyl ivermectin, were identified under both in-vivo and in vitro conditions. 
Zeng et al. (1996) investigated in vitro metabolism of abamectin and ivermectin using rat 
microsome and found three different metaboltes, identified as 24-hydroxymethyl, 26- 
hydroxymethyl, and 3”-0-desmethyl abamectin or ivermectin, respectively. 
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Argentine et al. (1992) studied abamectin metabolism iti vivo and in vitro 
conditions using susceptible and abamectin-resistant strains of CPB. They found an 
additional unidentified metabolite eluted 14 min following sample injection onto a 
reverse phase-high performance liquid chromatography (RP-HPLC). The fraction 14 
metabolite was more hydrophilic than the 3”-0-desmethyl and less hydrophilic than the 
24-hydroxymethyl metabolites, respectively. Enhanced metabolism occurred in two 
abamectin resistant strains (AB-F and AB-L) compared to the abamectin-susceptible 
strain (SS) under both in vivo and in vitro conditions and resulted in a 1.9-2.6-, 2.6-3.2-, 
1.2-1.8-fold increase of the 24-hydroxymethyl (24-OH), 26-hydroxymethyl (26-OH), and 
3”-0-desmethyl (3”DM) metabolites, respectively. 
Resistance to avermectins also has been reported in nematode parasites and other 
insect pests. Gill et al. (1991) investigated resistances to the avermectins in field 
populations of Haemonchus contortus using motility bioassay (Pong et al., 1980; Kass et 
al., 1980) and determined a population (Tulach) from Africa was similarly resistant to 
avermectins. Gopal et al. (1999) reported resistance to ivermectin in Trichostrongylus 
colubriformis judged by fecal egg counts and larval development assays. Le Jambre et 
al. (2000) elucidated genetics of avermectin resistance in a strain of Haemonchus 
contortus from Australia. They concluded that the resistance was autosomal and 
completely dominant in larvae but sex-linked in adults. 
Dent et al. (2000) elucidated a molecular mechanism of ivermectin resistance in 
C. elegance. They cloned and expressed three glutamate-gated Cf channel subunits 
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(GluClal, GluCla2, GluCla3) from resistant strain of C. elegance and performed 
functional assays using electrophysiolgical and molecular biological approaches. They 
determined that ivermectin resistance (4000-fold) was associated with mutations in the 
glutamate-gated Cf channel genes. Additional mutation, which caused decreased 
membrane permeability of ivermectin, was also characterized. Kono and Scott (1991) 
and Scott (1995) investigated avermectin resistance in the house fly, Musca domestica. 
From bioassay data using avermectin Bia and the metabolic synergists PBO, DEF, and 
DEM, they determined a 5.9 to 60,000-fold level of resistance among four strains. The 
resistance in two strains was reduced (5.6- to 8.5-fold decreased) but not completely 
abolished in the presence of PBO and was not suppressed in the other two strains by PBO, 
DEF, or DEM, indicating only partial involvement of monooxygenases for detoxification 
and resistance. Reciprocal crosses between susceptible and resistant strains indicated 
the resistance was autosomal, completely recessive, and polyfactorial. Pharmacokinetic 
studies revealed reduced penetration of radiolabeled abamectin as a resistance mechanism. 
Receptor binding studies with [ H]abamectin also indicated an altered target site 
insensitivity mechanism for resistance. 
Argentine et al. (1992) and Clark et al. (1992) elucidated resistance mechanisms 
of abamectin in CPB. Reciprocal backcross studies revealed that the abamectin 
resistance was autosomal, incompletely recessive, and polyfactorial. Bioassay, 
synergism studies and pharmacokinectic analysis indicated that increased oxidative 
metabolism and carboxylesterase activity contributed to abamectin resistance in two 
13 
resistant strains of CPB (AB-F and AB-L). Pharmacokinetic studies using 
[3H]avermectin Bia showed significantly increased production of metabolites in AB-F 
and AB-L when compared to susceptible strain (SS). In vitro metabolism of 
[3H]avermectin Bja using microsome samples was also significantly increased in both 
AB-F and AB-L strains when compared to SS strain. 
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ch2oh 
i=o 
Dexamethasone (DEX) 3-methylcholanthrene (3-MC) 
O. 
c2h5 
NH 
Phenobarbital (PB) 
Figure 1.1. Structures of the chemical inducers of cytochrome P450 monooxygenases. 
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0^^\zCH20CH2CH20CH2CH20C4H9 
o 
ch2ch2ch3 
Piperonyl butoxide (PBO) 
Troleandomycin (TAO) 
Figure. 1.2. Structures of the inhibitors of oxidative metabolism. 
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R1 • R2 R3 R4 R5 C22-X-C23 
Ala 
ch3 ch3 C2H5 H H -CH=CH- 
Alb ch3 ch3 ch3 H H -CH=CH- 
Bia ch3 H C2H5 H H -CH=CH- 
Bib ch3 H ch3 H H -CH=CH- 
A2a ch3 ch3 C2H5 H H /OH 
-CH2-CH- 
A2b ch3 ch3 ch3 H H /OH 
-CH2-CH- 
B2a ch3 H C2H5 H H /OH 
-CH2-CH- 
B2b ch3 H ch3 H H /OH 
-CH2-CH- 
24-OH ch3 H C2H5 H OH -CHCH- 
26-OH ch3 H C2H5 OH H -CH=CH- 
3”DM H H C2H5 H H -CH=CH- 
Ivermectin ch3 H >80% C2H5 
<20% CH3 
H H 
-CH2-CH2- 
Figure 1.3. Structures of the avermectins and their metabolites. 
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CHAPTER II 
MATERIALS AND METHODS 
A. Insect Strains and Rearing Conditions 
An insecticide-susceptible strain (SS) of Colorado Potato Beetle (CPB, 
Leptinotarsa decemlineata Say) was graciously supplied by Dr. G. G. Kennedy (North 
Carolina State University, Raleigh, NC) and has been in colony at the University of 
Massachusetts for over 15 years. An abamectin-resistant strain (AB-Fd) of CPB was 
originally collected from potato fields in Hadley and South Deerfield, MA (Argentine and 
Clark, 1990) and periodically topically-selected with abamectin to maintain resistance. 
The CPB strains were reared in aluminum and fiber-glass screen cages with wooden 
bottoms (0.7 m X 0.9 m X 0.5 m) and fed potato plants (Superior, Solarium tuberosum L.). 
The CPB rearing room was maintained at 27±2 °C, 50-85% RH, and with a photoperiod 
of 16:8 (L:D). 
B. Chemicals 
[3H]avermectin Bia, labeled at the C5-position (specific activity 11.35 mCi/pmol), 
was a gift from Merck, Sharpe and Dohme (Three Bridges, NJ). Abamectin (93% 
purity) was donated by Merck, Sharpe and Dohme (Raway, NJ). Piperonyl butoxide 
(PBO, 98% purity) and 3-methylcholanthrene (3-MC, 99.5% purity) were purchased 
from Chem Service (West Chester, PA). Dexamethasone (DEX, 95% purity), 
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phenobarbital (PB, 98% pure), troleandomycin (TAO, 97% pure), and epoxysuccinyl-L- 
leucylamido-(4-guanidino)- butane (E-64, 99% prue) were obtained from Sigma-Aldrich 
(St. Louis, MO). All other chemicals were purchased commercially and were highest 
grade available. 
C. Induction of P450s 
1. Induction via Ingestion. Artificial diet was freshly prepared for the 
gastrointestinal induction of P450s. The inducer compound (PB, 3-MC, or DEX) was 
dissolved or suspended in distilled, deionized water (0.25% w/v). Agar (0.03% w/v, 
DIFCO Laboratories, Detroit, MI) was added to the solution or suspension and heated 
just to the boiling point. Potato flakes (0.5 g/ml, Idahoan Foods, Lewisville, ID) were 
added to the agar suspension to encourage CPB feeding. The artificial diet was allowed 
to solidify at room temperature. For a control artificial diet, agar was prepared as above 
but without inducers. Individual late third or early fourth instars were placed separately 
into each well of a 12 well plate (Corning Cell Wells™, Corning, NY) and fed only the 
artificial diet during the induction period (24 hr). 
2. Induction via Dermal Penetration. The inducer compound (DEX or 3-MC) 
was dissolved in acetone and applied to the third dorsal abdominal segment of late third 
or early fourth instars with a microapplicator (Model M, ISCO, Lincoln, NB) using a 100 
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pi glass syringe (Hamilton Co., Reno, NV). DEX or 3-MC was applied as a 1.0 pi 
aliquot that produced approximately 10% mortality (LDio, Logit analysis, POLO-PC, 
LeOra Software, 1987). Control larvae were treated with 1.0 pi of acetone only. Up to 
25 treated larvae were placed onto cut potato stalks held in aquapics (Aquapic, Kokomo, 
IN) and inserted into a 1-quart glass jar for bioassay of induced versus non-induced 
beetles. 
To remove potato plant pigment, treated larvae were placed onto a Petri dish (100 
x 15 mm, Fisher Scientific Co., Pittsburgh, PA) containing only potato tuber slices for at 
least 16 hr prior to conducting studies on the phamacokinetics and in vivo metabolism 
studies with [3H]avermectin Bja and prior to the preparation of microsomes (see section 
E-G below). 
D. Bioassavs and Statistical Analysis 
Induced and non-induced fourth instars (65-85mg, 73.7 mg ± 6.2) were used in 
all bioassays. Abamectin was dissolved in acetone. The application of abamectin 
followed the same procedure as that used in the dermal penetration/acetone applications 
for induction. Up to 25 treated larvae were placed on cut potato plant stalks fixed in 
aquapics (Aquapic, Kokomo, IN) containing tap water and housed in a one quart glass jar. 
Mortality was determined 72 hr after treatment. A larva was considered dead if it failed 
to right itself in a 1 min interval after being placed on its back or if it weighed less than 
65 mg. Piperonyl butoxide (PBO), an oxidative synergist, was applied to the fourth- 
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instars to saturate microsomal monooxygenase detoxification mechanisms 1 hr prior to 
abamectin application. PBO (5 pg/larva, LDio dose) was topically applied in the same 
manner as for abamectin and inducer applications described previously. Synergistic 
ratio (SR) and relative percent synergism (R%S) values were calculated to determine if 
the tolerance to abamectin in CPB was increased by PBO pretreatment using the 
calculations given by Argentine et al. (1992). 
Bioassay data was subjected to logit mortality versus log dose analysis for 
determination of LD50 and LD95 values (POLO-PC, LeOra Software, 1987). Maximum 
log-likelihood ratio test was used to test the hypothesis of parallelism and equality {P = 
0.05) of the regression lines. 
1 • 1 
E. Pharmacokinetics and In Vivo Metabolism of \ HI Avermectin B^ 
Induced and non-induced fourth-instars (75-95 mg) were treated with 
o 'j 
[ Hjavermectin Bia (6 nCi/larva, 0.46 ng/larva). [ Hjavermectin Bia was topically 
applied using the same method used for inducer, abamectin, or PBO applications 
previously described. Larvae (one larva/vial) were placed into 20 ml glass vials at 22 
°C for six hours to collect urine and feces. After removing the larvae, [ Hjavermectin 
Bia and its metabolites in the excrement were extracted from the five replicate vials by 
two sequential extractions with ethyl acetate (2.5 ml/extraction) and one extraction with 
2.5 ml of methanol. For the first extraction, an aliquot of ethyl acetate was transferred 
to the first vial and vortexed for 10 sec. This extract was transferred to the second vial, 
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vortexed, and transferred sequentially through to the fifth vial. The extract from the 
fifth vial was transferred to a clean glass test tube. The second extraction with ethyl 
acetate and the third extraction with methanol followed the same protocol and all extracts 
were combined. After centrifugation at 500g to pellet feces and debris, the extract was 
decanted into a clean glass test tube and evaporated just to dryness under N2 at 50 °C or 
under vacuum (SpeedVac, Savant Instruments, Inc., Holbrook, NY). Methanol (120 pi) 
was added to the tube and the residue resuspended by gentle vortexing for 30 sec. A 20 
pi aliquot was transferred into a polyethylene scintillation vial, evaporated under N2 at 
50°C, and resuspended into 3 ml of liquid scintillation counting solution. An identical 
20 pi aliquot was injected into a high pressure liquid chromatograph (HPLC) for 
determination of avermectin Bia and its metabolites (Maynard et al., 1990). Reverse 
phase chromatography was performed using a Cig stationary phase (Zorbax ODS column, 
4.6 mm x 25 cm, DuPont Co., Wilmington, DE) and a mobile phase of methanol:distilled 
deionized water (85:15) at 1 ml/min. Fractions were collected at 1 min intervals for 30 
min using a fraction collector (Eldex Laboratories, Inc., Napa, CA). HPLC fractions 
were evaporated to dryness under N2 or vacuum at 50 °C and resuspended into 3 ml of 
liquid scintillation counting solution. The amount of [3H]avermectin Bia and its 
metabolites were quantified using a 1209 Rackbeta Liquid Scintillation Counter (Wallac 
Inc., Gaithersburg, MD). 
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F. Putative Structural Identification of HPLC Fraction 14 as 26-OH r3fflavermectin Bia 
Fraction 14, an unidentified metabolite of [ Hjavermectin Bia produced by CPB 
in vivo, was collected as described above and stored for structural identification 
(Agentine et al., 1992). Pooled fraction 14 samples were dried completely under N2 at 
50 °C and stored in -80°C. This procedure was repeated until approximately 6.5 ng of 
fraction 14 was collected. Instrumental analysis was accomplished in conjunction with 
Dr. J. O. Nelson’s research group (Mass Spectrometry Facility, University of Maryland, 
College Park, MD). The fraction 14 metabolite was analyzed by capillary HPLC/MS 
using electrospray ionization in the positive ion mode. Reverse phase capillary HPLC 
utilized a micro LC system (Micro-Tech Ultra-Plus II, Micro-Tech Scientific, Inc., 
Sunnyvale, CA) equipped with a 0.32 mm inside diameter (ID) X 150 mm Ci8 capillary 
column (Zorbax 300SB-C18, 5 p). Two solvent systems were used for the mobile phase. 
The first solvent system (Solvent A) containing distilled deionized water (dd H20), 
acetonitrile, acetic acid, and TFA in the ratio of 95:5:0.1:0.01 by volume. The second 
solvent system (Solvent B) containing dd H20, acetonitrile, acetic acid, and TFA in the 
ratio of 5:95:0.1:0.007 by volume. Both solvent systems were delivered at a combined 
flow rate of 5 pl/min using a gradient 90% of Solvent A and 10% Solvent B as the initial 
composition; which changed to 80% Solvent A and 20% Solvent B at 1.0 min; 10% 
Solvent A and 90% Solvent B at 4.0 min; 5% Solvent A and 95% Solvent B at 50 min; 
and returning to the initial composition at 60 min. Eluted sample was detected by UV 
absorbance recording at 245 nm. The outlet of the UV detector was connected to the 
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electron spray ionization (ESI) source by a short length (35 cm) of 5 p ID fused silica 
capillary column. Positive ion ESI mass spectra were collected on a ion trap mass 
spectrometer (Finnigan LCQ, ThermoQuest Corp., San Jose, CA) over a mass range of 
300 to 2000 mass/charge (m/z). The ESI conditions were: spray voltage 5 kV; capillary 
temperature at 200 °C; nitrogen gas sheath 50; and capillary voltage 3 V. 
G. Microsome Preparation 
Protocols for microsome preparation was adapted from Argentine et al. (1992) 
with modifications. Induced and non-induced fourth instars were fed potato slices for 
16 hr to purge potato leaf pigments from the midgut. On an ice-chilled glass plate, 
larvae were decapitated to avoid eye pigment contamination. The remaining body parts 
(abdomen and thorax) were homogenized in 0.2 M potassium phosphate buffer (pH 7.8) 
containing 20% glycerol, 0.1 mM dithiothreitol (DTT), 0.4 mM phenyl-methylsulfonyl 
fluoride (PMSF), ethylenediaminetetraacetic acid (EDTA) free protease inhibitor 
(Complete™, Roche Diagnostics Corp., Indianapolis, IN), and 0.028 mM epoxysuccinyl- 
L-leucylamido-(4-guanidino)-butane (E-64) by seven gentle strokes using a Potter- 
Elvehjem homogenizer at 4 °C. The homogenate was centrifuged at 13,000g for 15 min 
at 4 °C. The supernatant was transferred into a clean tube and centrifuged at 105,000g 
for 60 min at 4°C. The microsomal pellet was resuspended in 0.05 M Tris-base/HCl 
(pH 7.9) containing 20% glycerol for determination of cytochrome P450 and P420 
content and for in vitro metabolism of [3H]avermectin Bia (section I and J, respectively). 
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H. Protein Determination 
The concetration of microsomal protein was determined using the bicinchoninic 
acid (BCA) method (Smith et al., 1985). Microsomal and bovine serum albumin (BSA) 
protein samples were incubated with one part of copper (II) sulfate pentahydrate 
(CuS04«5H20) and 50 part of BCA at 37°C for 30 min. Absorbance (O. D.) of 
incubated microsomes and standard BSA samples were determined at 562 nm using 
Shimadzu 210UV double-beam spectrophotometer (Shimadzu Seishakusho LTD., Kyoto, 
Japan). A standard BSA protein concentration versus O. D. curve was constructed and 
microsomal protein concentrations were determined directly from the standard curve. 
I. Determination of Cytochrome P450/P420 Contents 
Cytochrome P450 and P420 levels were determined using the carbon monoxide 
(CO)-difference method of Omura and Sato (1964) with modification by Jesudason et al. 
(1988). Sodium dithionite (2.5 mg/ml) was added to the induced and non-induced 
microsomal samples (1 mg protein/ml). Each microsomal sample was divided into two 
test tubes. One sample was bubbled with CO for 15 sec and transferred to the sample 
cuvette. The other sample was transferred to the reference cuvette without the addition 
of CO. The cuvettes were placed in a double-beam spectrophotometer and cytochrome 
P450 content quantified using an extinction coefficient of 91 cm"1 mM'1 for absorbance 
differences between 450 and 490 nm. The amount of cytochrome P420 content was 
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determined using an extinction coefficient of 110 cm"1 mM"1 for the absorbance 
difference between 420 and 490 nm. 
J. In Vitro Metabolism of [3HJavermectin 
The difference of in vitro oxidative metabolism of [HJavermectin Bia in 
microsomal preparations from dexamethasone (DEX)-induced and non-induced SS CPB 
larvae was determined using microsomes that were prepared as described previously 
except glycerol was not added to the homogenization buffer (See section G). The 
reaction mixture, which containing 50 pi of microsome and a NADPH regenerating 
system (2.5 mM glucose 6-phosphate, 0.25 mM NADP+, 25 mM MgCf, and 2 units of 
glucose-6-phosphate dehydrogenase/ml), was incubated with 46 nCi [ HJavermectin Bla 
(2.7 nM, 0.33% acetone final concentration) at 37 °C for 60 min. In order to validate 
the occurrence of oxidative metabolism, microsomes were preincubated with the 
oxidative inhibitors, piperonyl butoxide and troleandomycin (10"4 M), and with a 
NADPH regenerating system for 10 min prior to the addition of [ HJavermectin Bia. 
The reactions were stopped by addition of 100 pi methylene chloride. The mixture was 
centrifuged at 10,000g and the supernatant transferred to a clean tube. The sample was 
sequentially extracted with 100 pi methylene chloride and 100 pi of ethyl acetate. The 
combined organic extracts were dried under N2 or using vacuum and resuspended into 
120 pi methanol for HPLC analysis. As described previously, 30 fractions were 
collected from the HPLC separation, dried under N2 or using vacuum at 50 °C, and 
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resuspended into 3 ml of scintillation counting solution. The relative amount of each 
metabolite was determined by liquid scintillation spectrophotometry as before. 
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CHAPTER III 
RESULTS AND DISCUSSION 
A. Comparison of Abamectin Tolerance following DEX, 3-MC, or PB induction 
DEX-, 3-MC-, and PB-induced and non-induced 4th instars from both SS and 
AB-F strains of CPB were selected by weight (65-75 mg, 73.7 mg ± 6.2 S.D.) to 
minimize experimental error from differences in body weight. Logit analysis was used 
to generate LD5o and LD95 values and maximum likelihood ratio tests were conducted to 
determine the equality and parallelism of regressions in order to establish statistical 
significance of treatments (Table 3.1). 
DEX-induced beetles of SS strain exhibited a significantly decreased mortality 
response to abamectin compared to non-induced SS beetles (j? = 8.2, df= 2, P = 0.017) 
(Figure 3.1). 3-MC-induced beetles of SS strain likewise elicited a significantly 
decreased mortality response to abamectin compared to non-induced SS beetles (jf = 
18.9, df- 2, P < 0.001) (Figure 3.2). In contrast, PB-induced beetles of SS strain were 
not statistically different in their mortality response to abamectin compared to non- 
induced SS beetles even though a consistent decrease in the mortality response was 
observed (jf = 5.0, df= 2, P = 0.081) (Figure 3.3). 
PB-induced beetles of AB-F strain were not significantly different in their 
mortality response to abamectin compared to non-induced AB-F beetles (j^2 = 2.9, df= 2, 
P = 0.238) (Figure 3.4). 
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The slopes of the log abamectin dose versus logit percent mortality curves for 
DEX-, 3-MC-, and PB-induced beetles of SS strain (Figures 3.1, 3.2, 3.3, respectively) 
were statistically the same as for non-induced SS beetles (DEX; ^ = 0.3, df= 1, P = 
0.566: 3-MC; £ = 3.2, df= 1, P = 0.460: PB; £ < 0.01, df= 1, P = 0.925, respectively). 
Likewise, the slope of the log abamectin dose versus logit percent mortality curves for 
PB-induced beetles of AB-F strain (Figure 3.4) were statistically the same as for non- 
induced AB-F beetles (j? = 2.0, df= 1, P = 0.153). 
The tolerance of induced and non-induced beetles of SS strain to abamectin was 
compared using an induction ratio (IR, Table 3.1). Based on IR values determined from 
both LD50 and LD95 values, DEX-induced beetles were ~2.3-fold more tolerant to 
abamectin than non-induced beetles and 3-MC-induced beetles were -3.1-3.6-fold more 
tolerant to abamectin than non-induced beetles. Although the PB-induced beetles were 
-1.9-fold more tolerant than the non-induced SS beetles and the PB-induced beetles of 
AB-F strain were ~1.2-fold more tolerant to abamectin than non-induced AB-F beetles, 
their differences are not statistically significant. 
Significantly decreased abamectin mortality in DEX- and 3-MC-induced beetles 
of SS strain compared to non-induced SS beetles indicates that inductions by DEX and 3- 
MC results in increase of tolerance to abamectin in CPB. However, the mortality 
response to abamectin in PB-induced beetles of SS and AB-F strains compared to non- 
induced SS and AB-F beetles, respectively, was not significantly different and indicates 
that induction by PB in both strains does not affect abamectin tolerance. 
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DEX-, 3-MC-, and PB-induced SS and PB-induced AB-F beetles resulted in no 
significant change in the slopes of their dose response curves compared to that obtained 
with non-induced beetles of SS and AB-F strains, respectively. This result is indicative 
of a common mechanism of toxicity in CPB to abamectin, which is not altered either by 
induction or by previous selection with abamectin. 
Yu and Terriere (1973) reported that PB-induced houseflies elicited significantly 
decreased mortality response to propoxur, a carbamate insecticide, compared to non- 
induced houseflies but 3-MC-induced houseflies exhibited statistically similar mortality 
response to propoxur compared to non-induced houseflies. It is unknown why 
glucocorticoid compounds, such as DEX and 3-MC, are superior inducers compared to 
barbiturates, such as PB, in CPB resulting in decreased abamectin mortality or why PB is 
superior inducer compared to 3-MC in housefly, resulting in decreased propoxur 
mortality. Nevertheless, water solubility of inducer and insecticide might be a key 
factor in this case. Abamectin, DEX and 3-MC are only slightly water-soluble or 
completely water-insoluble (abamectin, 0.01 pg/ml; DEX, 100 jug/ml; 3-MC, insoluble; 
respectively). Conversely, propoxur and PB are relatively more water-soluble (propoxur, 
2 mg/ml; PB, 1 mg/ml; respectively). The above results suggest that different induction 
patterns of glucocorticoid inducers (DEX and 3-MC) compared to a barbiturate inducer 
(PB) have occurred in CPB and housefly and play a critical role in increased tolerance to 
insecticides and resistance. 
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The larger IR values of 3-MC-induced SS beetles compared to DEX-induced 
beetles indicate that 3-MC is a superior inducer in this specific case. However, the IR 
values of DEX- and 3-MC- versus PB-induced beetles cannot be compared directly 
because the induction processes used were different. PB induction used a 
gastrointestinal route since PB is highly water soluble. A cuticular-topical induction 
route was used for DEX and 3-MC because of their higher lipophilicity. 
PB-induced and non-induced AB-F beetles exhibited lower mortality to 
abamectin compared to PB-induced and non-induced SS beetles, respectively. This 
finding is expected because the AB-F strain is already resistant to abamectin (~8-11-fold 
more resistant compared to SS strain, Argentine et al., 1992). The lack of PB-induction 
may indicate that the resistance mechanism is already constitutively expressed and not 
further inducible by PB or simply that abamectin metabolism is not inducible by PB. 
B. In Vivo Synergism of Abamectin Toxicity 
To determine whether oxidative metabolism was involved in the mortality 
th 
response of CPB to abamectin (Argentine et al., 1992), 4 instars were induced with 
DEX, 3-MC, and PB for 24 hr and then pre-treated with the oxidative synergist PBO (5 
pg/larva) or acetone (solvent control) for 1 hr prior to abamectin treatment. Mortality 
responses to abamectin were determined and analyzed as before and comparisons 
between PBO synergized and unsynergized (acetone only) beetles were made (Figure 3.5 
and Table 3.2). 
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In DEX- and 3-MC-induced beetles, the abamectin mortality responses of the 
PBO synergized groups were significantly higher compared to the unsynergized beetles 
(DEX; £ = 9.4, df — 2, P = 0.009: 3-MC; $ = 10.6, df = 2, P = 0.005, respectively, 
Figure 3.5). In PB-induced beetles, the abamectin mortality response of the PBO 
synergized group was not significantly different from the unsynergized group (PB; £ — 
2.9, df — 2, P = 0.235) (Figure 3.5). 
In DEX-, 3-MC-, and PB-induced beetles, the slopes of the log abamectin dose 
versus logit percent mortality curves for the PBO synergized groups were not statistically 
different from the slopes of the unsynergized beetles (DEX; £ - \ .2,df= 1, P = 0.272: 3- 
MC; £ = 0.2, df= P = 0.594: PB; £ = 0.06, df— 1, P = 0.794), respectively. 
PBO-based synergistic ratios (SRs) using LD50 values of DEX-, 3-MC-, and PB- 
induced beetles versus unsynergized beetles were DEX-SR (2.4) > 3-MC-SR (2.3) >> 
PB-SR (1.7), respectively (Table 3.2). 
In summary, substantial and significant synergism by PBO pre-treatments in 
DEX- and 3-MC-induced beetles indicates that oxidative metabolism of abamectin is 
likely increased by the induction process and may be the primary mechanism resulting in 
increased tolerance to abamectin. The mortality response to abamectin was not 
significantly synergized by PBO in PB-induced beetles indicating that oxidative 
metabolism of abamectin is not likely increased by PB treatment and is consistent with 
the lack of significantly increased survivorship of PB-induced beetles in the presence of 
abamectin. PBO synergisms of DEX-, 3-MC-, and PB-induced beetles resulted in no 
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significant change in the slopes of their log abamectin dose response versus logit percent 
mortality curves compared to that obtained with unsynergized but induced beetles. This 
finding is consistent with a common mechanism of toxicity to abamectin in CPB, which 
is attenuated by enhanced oxidative metabolism elicited by the inducer compounds. 
The higher SR values of DEX- and 3-MC-induced beetles compared to PB-induced 
beetles indicate that DEX and 3-MC are superior inducers for oxidative metabolism of 
abamectin than PB. Similar SR values obtained with DEX- and 3-MC-induction 
indicate that these two inducers produce similar level of oxidative metabolism of 
abamectin in CPB. 
C. Putative Structural Identification of HPLC Fraction 14 as 26-hydroxymethvl 
r3Hlavermectin B_iA26-OH) 
An unidentified metabolite of [3H]avermectin Bia (fraction 14), which was eluted 
with reverse phase HPLC at retention time (RT) of 14-15 min, was accumulated as 
described by Argentine et al. (1992). The accumulated fraction 14 sample was resolved 
into a complex of UV absorption peaks with retention time between 10 and 30 min using 
capillary HPLC equipped with UV detector (Figure 3.6). The eluted compounds were 
further analyzed using electron spray ionization (ESI) and ion trap mass spectrometry to 
generate total ion current and mass chromatograms. The total ion current chromatogram 
(Figure 3.7, panel A) also revealed a complex of compounds as expected. However, the 
total ion current chromatogram of masses 889.0-890.0 m/z (Figure 3.7, panel B), which 
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encompasses the expected mass of 26-OH metabolite (889.6), gave a single peak with a 
RT of 20.2 min. Lastly, the expanded mass chromatogram of the ion current peak at 
retention time 20.2 contained a base peak of 889.6 m/z (Figure 3.7, panel C). 
Since fraction 14 was obtained from the crude extract of CPB excrement, many 
organic compounds were co-eluted and resulted in a complex of UV absorbing molecules 
(Figure 3.6) and a complex total ion current chromatogram (Figure 3.7, panel A). 
Nevertheless, only a single ion current peak (RT = 20.2) accumulated masses in the range 
of 889.0-890.0 m/z and contained a base peak of mass 889.6 m/z in its mass 
chromatogram. These findings are consistent with the mass of avermectin Bia (873.1) 
plus one oxygen (15.99), which is the expected mass of hydroxylated avermectin Bia 
(889.1). 
Although there was not enough sample for MS/MS or NMR analysis of fraction 
14, the results obtained above are consistent with those published by Zeng et al. (1996). 
In their investigation, an unidentified avermectin Bia metabolite, which was more 
hydrophobic than 24-OH but less lipophilic than 3”DM or. avermectin Bia, was 
determined to be the 26-OH metabolite of avermectin Bia by MS/MS and NMR. Our 
HPLC-based protocol to separate avermectin Biafrom its primary metabolites (3”DM, 
24- and 26-OH) was identical to the one evaluated by Zeng et al. (1996) and produced 
similar, if not identical, separations. Therefore, it is highly likely that fraction 14 contains 
the 26-OH metabolite of avermectin B|a but this identification is tentative without 
corroborative NMR information. 
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• • 'X 
D. Pharmacokinetics off Hlavermectin 
-5 
The type and the relative amounts of [ HJavermectin B]a metabolites using DEX-, 
3-MC-, PB-induced (24 hr induction via ingestion) and non-induced 4th instar SS beetles 
were determined to compare differences of in vivo metabolism (Figure 3.8). Reverse 
phase HPLC separation and liquid scintillation quantification of the extracts from the 
larval excrement showed that three oxidative [ H]avermectin Bia metabolites were 
present in the extracts and were the same as previously reported by Argentine et al. 
(1992): 24-hydroxymethyl (24-OH), 26-hydroxymethyl (26-OH, formally fraction 14), 
and 3”-0-desmethyl (3”DM) avermectin Bjaeluted at retention times of 3-4, 14-15, and 
19-20 min, respectively. 
For determination of the relative amounts of these three [ HJmetabolites, eluted 
HPLC fractions were quantified by liquid scintillation analysis (Table 3.3). DEX- 
induced beetles produced a significantly higher amount of the 3”DM metabolite (63.9 % 
more) compared to non-induced beetles (/-test, P < 0.05). DEX-induced beetles also 
produced increased amounts of the 24-OH and 26-OH metabolites (44.7 and 41.2 % more, 
respectively) but these values were not statistically different when compared to non- 
induced beetles (/-test, P > 0.05) (Figure 3.8 and Table 3.3). 3-MC-induced beetles 
produced significantly higher amounts of the 24-OH, 26-OH, and 3”DM metabolite (50.9, 
53.5, and 53.2 % more, respectively) compared to non-induced beetles (/-Test, P < 0.05). 
PB-induced beetles produced slightly increased amounts of the 24-OH, 26-OH, 3”DM 
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metabolites but none of these values were statistically different from non-induced beetles 
(Mest, P > 0.05). 
Significantly increased production of the 3”DM metabolite due to enhanced 
oxidative metabolism in DEX-induced beetles indicates that DEX is involved in a unique 
induction pathway but less involved in productions of the two hydroxylated metabolites 
(24-OH and 26-OH). In contrast, significantly increased productions of all three 
metabolites (24-OH, 26-OH, and 3”DM) in 3-MC-induced beetles suggest that 3-MC is 
involved in multiple induction pathways, including oxidative hydroxylations and 3”-0- 
desmethylation. Thus, DEX induction favored the production of the 3”DM metabolite 
whereas 3-MC induction favored the production of all three metabolites. This result is 
similar to the report by Zeng et al. (1996). According to their results, DEX-induced rat 
microsomal fractions increase the formation of 3”DM metabolite of abamectin and 3- 
MC-induced microsomes increased the formation of 24-OH and 26-OH metabolites of 
abamectin. Marginal production of [ Hjavermectin Bia metabolites (24-OH, 26-OH, 
and 3”DM) by PB-induced beetles indicates only low involvement of PB induction in the 
oxidative metabolism of [ HJavermectin Bia. 
In summary, DEX is a selective inducer for 3”DM metabolite production and 3- 
MC is a more broad-spectrum inducer resulting in the increased production of all three 
metabolites (24-OH, 26-OH, and 3”DM). PB is apparently the weakest inducer for CPB 
compared to DEX or 3-MC since the mortality response (Figure 3.3) and 
pharmacokinetics studies in PB-induced beetles showed only slight increases in 
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abamectin tolerance and [JH]avermectin Bia metabolite production that were not 
statistically significant, respectively. 
E. Microsomal Cytochrome P450/P42Q Levels 
A modified method of microsome preparation adapted from Argenitne et al. 
(1992) was utilized for consistent preparation of enzymatically-active microsome. Total 
protein in DEX-induced microsomal preparations (10.2 pg/pl ±1.1, mean ± S.D.) was 
not significantly different from total protein in non-induced microsomes (12.7 pg/pl ± 1.9, 
mean ± S.D.) (Mest, P > 0.05). However, the level of cytochrome P450s (determined 
from the CO-difference spectra) from DEX-induced microsomes were significantly 
elevated (1.9-fold) compared to non-induced microsomes (Mest, P < 0.05) (Table 3.4). 
Cytochrome P420, an inactivated form of cytochrome P450, was not detected in the 
spectrophotometric analysis with this modified method. 
Since CPB has evolved a complex protease system to break down ingested 
proteins of Solanaceous plants (Gruden et al., 1998), inhibition of various proteases in 
CPB homogenate is important to protect P450s from degradation. The use of 
Complete™, which inhibits a broad spectrum of serine and cysteine proteases, and E-64, 
which is a cysteine specific protease inhibitor, results in more consistent microsome 
preparation, that augments cytochrome P450 and limits cytochrome P420 occurrence. 
Significantly elevated production of cytochrome P450 in DEX-induced 
microsome compared to non-induced microsomes indicates DEX induction causes 
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increase in production of P450 in CPB. The exact induction mechanism is not 
completely understood. However, members of P450 family (CYP3A) that are inducible 
with DEX have been identified in several mammalian species, including human and rat 
(Telhada et al., 1992; Schuetz et al., 1984; Schuetz and Guzelian, 1984). Schuetz and 
Guzlian showed that the mechanism of induction of CYP3A with DEX is distinct from 
the mechanism of induction with other glucocorticoids, such as pregnenolone 16a- 
carbonitrile (PCN, a prototypical inducer of CYP3A). PCN acts as an agonist on 
glucocorticoid receptor (GR) by inducing tyrosine aminotransferase (TAT), which is 
necessary for forming a complex with GR that binds to glucocorticoid responsive element 
(GRE) on 5’ flanking region of CYP3A. PCN antagonizes DEX induction of TAT 
Therefore, their results suggest DEX treatment causes induction of a unique cytochrome 
P450 isoform. 
F. In Vitro Metabolism of \ Hlavermectin Bia 
3 The in vitro metabolism of [ HJavermectin Bia was performed to determine types 
and relative amounts of avermectin metabolites formed in microsomal preparations. As 
expected from in vivo metabolism, three metabolites (24-OH, 26-OH, and 3”DM) were 
detected by reverse phase HPLC and liquid scintillation analysis (Figure 3.9). 
DEX-induced microsomes produced 2.3-fold more 3”DM metabolite than non- 
induced microsomes (Mest, P < 0.05). DEX-induced microsomes produced 1.2-fold 
less 24-OH metabolite and 1.7-fold more 26-OH metabolite but these values are not 
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significantly different from those obtained from the non-induced microsomes (7-test, P > 
0.05). 
PBO and troleandomycin (TAO) were added to DEX-induced microsome to 
investigate in vitro synergism (Figure 3.9). Both PBO- and TAO-treatment significantly 
reduced the microsomal production of 3”DM metabolite (9.3-fold and 10.1-fold less, 
respectively) compared to unsynergized microsome (/-test, P < 0.05). PBO-synergized 
microsomes produced 2.4-fold less 2.4-OH and 5.1-fold less amount of 26-OH 
metabolites but these values are not significantly different compared to unsynergized 
microsomes (/-test, P > 0.05). Likewise, TAO-synergized microsomes produced 3.1- 
fold less 24-OH and 5.5-fold less 26-OH metabolites but these values are not 
significantly different compared to unsynergized microsomes (/-test, P > 0.05). 
The above result clearly demonstrates that DEX-induced microsomes result in 
increased production of 3”DM metabolite only. Since DEX-induced microsomes elicits 
elevated levels of P450s compared to non-induced microsome (Table 3.4), increased 
production of 3”DM metabolite is strongly correlated with a specific induction pathway 
leading to elevated expression of a P450 isoform. In a similar in vitro metabolism study 
using rat microsomes by Zeng et al. (1996), CYP3A, inducible by DEX only, is the major 
isoform responsible for 3”-0-desmethylation of [ Hjavermectin Bia. 
Significantly reduced 3”DM metabolite production indicates PBO and TAO 
inhibits increased oxidative metabolism of [ Hjavermectin Bia by DEX-induced P450. 
The results of in vitro metabolism and in vitro synergism of [3H]avermectin Bia correlated 
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well with the decreased abamectin mortality in DEX-induced beetles compared to non- 
induced beetles and validates how the in vivo oxidative synergism of abamectin by PBO 
results in increased mortality in DEX-induced beetles compared to unsynergized but 
induced beetles (Figure 3.5 and Table 3.2). 
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Chapter IV 
CONCLUSIONS 
Oxidative metabolism of abamectin as a principal resistance mechanism in CPB 
was validated using DEX-, 3-MC-, and PB-induced beetles of SS and AB-F strains 
compared to non-induced beetles of SS and AB-F strains, respectively. Significantly 
decreased mortality response to abamectin in DEX- and 3-MC-induced SS beetles 
compared to non-induced SS beetles indicates that inductions by DEX and 3-MC result in 
an increase of abamectin tolerance in CPB (Figures 3.1 and 3.2; Table 3.1). However, 
the mortality response to abamectin in PB-induced SS and AB-F beetles compared to 
non-induced SS and AB-F beetles, respectively, was not significantly different indicating 
induction by PB in both strains did not affect abamectin tolerance (Figures 3.3 and 3.4; 
Table 3.1). 
Significant synergism by PBO in DEX- and 3-MC-induced SS beetles suggests 
that induction may cause increased oxidative metabolism of abamectin, which may be the 
mechanism involved in increased tolerance of abamectin (Figure 3.5; Table 3.2). The 
mortality response to abamectin was not significantly synergized by PBO in PB-induced 
SS beetles indicating that oxidative metabolism of abamectin is not likely increased by 
PB induction. 
The fraction 14 metabolite was tentatively determined as a 26-hydoxymethyl 
avemectin Bia (26-OH) (Figures 3.6 and 3.7). Results from reverse phase HPLC and 
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electron spray ionization (ESI) ion trap mass spectrometry were consistent with analytical 
studies by Zeng et al. (1996) even though there was not enough sample for MS/MS or 
NMR analysis of fraction 14 for complete structure identification. 
Three major metabolites of [3H]avermectin B)a (24-OH, 26-OH, and 3”DM), 
produced in vivo and in vitro, were the same as the three major metabolites produced in 
rat (Zeng et al., 1996) (Figures 3.8 and 3.9; Table 3.3). DEX-induced SS beetles and 
microsomes prepared from SS beetles produced significantly increased 3”DM metabolite 
compared to non-induced beetles and micorsomes indicating that DEX was involved in a 
unique induction pathway but less involved in productions of the two hydroxylated 
metabolites (24-OH and 26-OH). In contrast, 3-MC-induced beetles produced 
significantly more of all three metabolites (24-OH, 26-OH, and 3”DM), which suggest 
that 3-MC was involved in multiple induction pathways. Thus, induction by DEX 
favors the production of 3”DM metabolite whereas induction by 3-MC favors the 
production of all three metabolites. 
Production of 3”DM metabolite in DEX-induced microsomes was significantly 
inhibited by PBO and TAO in vitro (Figure 3.9). These results correlate well with the 
decreased abamectin mortality in DEX-induced beetles compared to non-induced beetles 
and validate the in vivo oxidative synergism of abamectin by PBO, which results in 
increased mortality response to abamectin in DEX-induced beetles compared to 
unsynergized but induced beetles. 
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The relationship between differential induction of P450s and abamectin 
metabolism is not clear. However, water solubility of inducer seems to be correlated to 
induction of specific P450 subfamilies and these induced P450s might be involved in 
metabolism of abamectin that has similar water solubility with inducer since the water 
solubility is an important factor that determines ligand-receptor interaction. 
There is a strong possibility that induction by DEX may result in elevated levels 
of a specific P450 subfamily leading to production of 3”-0-desmethyl [ HJavermectin 
B’ia (3”DM). Further studies, such as northern blot analysis and sequencing of DEX- 
induced P450 using primers designed for conserved regions of the CYP3A family of 
P450s and semi-nested PCR strategies, are needed to understand the differential induction 
P450 subfamilies and their role in abamectin metabolism that result in resistance. 
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Table 3.2. Effect of piperonyl butoxide (PBO, 5 pg/larva) synergistic pre-treatment on the 
mortality responses to abamectin in DEX-, 3-MC-, and PB-induced SS 4 instar CPB. 
SS Strain n LD50 _ Slope ± SE 
SRa 
DEX-induced + acetone 69 
(ng/larva plus 95% CL) 
1.58 (1.00-2.75) 3.69 + 1.19 
DEX-induced + PBO 69 0.65 (0.25-1.02)b 1.99 ± 1.02 2.4 
3-MC-induced + acetone 56 2.32(1.63-4.21) 4.68 ± 1.72 
3-MC-induced + PBO 52 1.03 (0.63-1.48)c 3.56 ± 1.27 2.3 
PB-induced + acetnone 64 1.02 (0.37-1.48) 4.00 ± 1.86 
PB-induced + PBO 51 0.60 (0.19-0.93) 3.40 ± 1.37 1.7 
a Synergistic Ratio (SR) = LDSo of induced and acetone pre-treated (solvent control) SS 
CPB/LD50 of induced and PBO pre-treated SS CPB for abamectin mortality. 
b Value is significantly different from that obtained using unsynergized (acetone only) 
DEX-induced beetles (£ = 9.4, df= 2 ,P = 0.009). 
c Value is significantly different from that obtained using unsynergized (acetone only) 3- 
MC-induced beetles (j£ = 10.6, df- 2, P = 0.005). 
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Table 3.3. Relative amount of [3H]avermectin Bu metabolites produced under in vivo 
conditions3 using induced and non-induced 4th instar SS CPB. 
[3H]avermectin Non-induced 
metabolites 
DEX-induced 3-MC-induced PB-induced 
-. u 
(% of total applied [3H]avermectin Bi a ± SD and net change in parenthesis ) 
24-OH 3.22 ±1.19 4.66 ± 0.58 4.86 ± 0.23c 4.35 ±0.62 
(1.44) (1.64) (1.13) 
26-OH 1.70 ±0.51 2.40 ± 1.08 2.61 ± 0.47° 1.82 ±0.36 
(0.70) (0.91) (0.12) 
3”DM 5.34 ± 1.89 8.75 ± 1.19° 8.18 ± 0.14c 6.13 ±2.38 
(3.41) (2.84) (0.79) 
a Extract from excrement collected from 4th instars at 6 hr post-topical application of 
[3H]avermectin Bia. 
b Net change value is the difference of the induced value minus non-induced value. 
c Significantly different from the non-induced population (/-test, P < 0.05). 
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Table 3.4. Comparative cytochrome P450 levels from DEX-induced and non-induced 4th 
instar SS CPB. 
Treatment Cytochrome P450 levels 
(pmole/mg protein ± SD) 
Non-induced 27.8 ±2.5 
DEX-induced 53.13 ± 10.2a 
a The cytochrome P450 levels from the microsomal fractions of DEX-induced SS CPB 
were statistically increased from the levels found in the microsomal fractions of non- 
induced SS CPB (/-test, P < 0.05). 
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Figure 3.1. Log abamectin dose versus logit mortality regressions of DEX-induced and 
non-induced 4th instar CPB of abamectin-susceptible (SS) strain. The two regression 
lines are significantly different from each other using the maximum likelihood ratio test 
(X2 = 8.2, df = 2, P < 0.05). 
49 
50 
Figure 3.2. Log abamectin dose versus logit mortality regressions of 3-MC-induced and 
non-induced 4th instar CPB of the abamectin-susceptible (SS) strain. The two regression 
lines are significantly different from each other using the maximum likelihood ratio test 
(x2= 18.9, df= 2, P<0.05). 
f 
51 
52 
Figure 3.3. Log abamectin dose versus logit mortality regressions of PB-induced and 
non-induced 4th instar CPB of the abamectin-susceptible (SS) strain. The two regression 
lines are not significantly different from each other using the maximum likelihood ratio 
test (x2 = 5.0, df = 2, P = 0.081). 
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Figure 3.4. Log abamectin dose versus logit mortality regressions of PB-induced and 
non-induced 4th instar CPB of the abamectin-resistant (AB-F) strain. The two regression 
lines are not significantly different from each other using the maximum likelihood ratio 
test (x2 = 2.9, df = 2, P = 0.238). 
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Figure 3.5. Effect of piperonyl butoxide (PBO, 5 mg) synergistic pre-treatment on the 
mortality response to abamectin in DEX-, 3-MC-, and PB-induced SS CPB 4th instars. 
Solid circle indicates PBO pre-treatment. Open circle indicates solvent (acetone) 
treatment only. 
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